The short version of cyclic heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-25. Anything still debated is marked as such rather than presented as settled.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Analysis of an intermediate plasminogen structure suggests that plasminogen conformational change to the open form is initiated through KR-5 transiently peeling away from the PAp domain. These movements expose the KR5 lysine-binding site to potential binding partners, and suggest a requirement for spatially distinct lysine residues in eliciting plasminogen recruitment and conformational change respectively.
=== Transition and swearing-in ceremony === Melo named Porto Alegre councilman and former mayor of Santa Maria, Cezar Schirmer, as his transition coordinator for the transition between the Marchezan government and his. In his inaugural speech on 1 January 2021, Melo affirmed that was necessary to "raise the optimism" for the city, as the city, due to the COVID-19 pandemic, had been going through rough times economically and socially.
The mass spectrometry of proteins has long been a useful technique for identifying posttranslational modifications and, more recently, for probing protein structure. Most proteins are difficult to purify in more than milligram quantities, even using the most modern methods. Hence, early studies focused on proteins that could be purified in large quantities, e.g., those of blood, egg white, various toxins, and digestive/metabolic enzymes obtained from slaughterhouses. Many techniques of protein purification were developed during World War II in a project led by Edwin Joseph Cohn to purify blood proteins to help keep soldiers alive. In the late 1950s, the Armour Hot Dog Co. purified 1 kg (= one million milligrams) of pure bovine pancreatic ribonuclease A and made it available at low cost to scientists around the world. This generous act made RNase A the main protein for basic research for the next few decades, resulting in several Nobel Prizes.
China was identified as interfering with the 2024 election through propaganda and disinformation campaigns linked to its Spamouflage operation. U.S. intelligence agencies described the effort as not targeting any particular candidate but focusing on issues important to the Chinese government, such as Taiwan, and "undermining confidence in elections, voting, and the U.S. in general". As early as April 1, 2024, The New York Times reported that the Chinese government had created fake pro-Trump accounts on social media "promoting conspiracy theories, stoking domestic divisions and attacking President Biden ahead of the election in November".
Sources: en.wikipedia.org
For some professional career programs, students are required to take the Saber-Pro test, in their final year of undergraduate academic education. Public spending on education as a proportion of gross domestic product in 2015 was 4.49%. This represented 15.05% of total government expenditure. The primary and secondary gross enrolment ratios stood at 113.56% and 98.09% respectively. School-life expectancy was 14.42 years. A total of 94.58% of the population aged 15 and older were recorded as literate, including 98.66% of those aged 15–24.
=== Research supporting the development, safety and benefits of GLP-1 therapeutics === Drucker joined the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto in 2006. In 2008 he led studies aimed at the development and testing of the first long-acting, once-weekly version of the diabetes medication exenatide. He later studied the long-term effects of related weight-loss medicines on bowel health. Drucker has also led the identification of the cardioprotective mechanisms of GLP-1 action. Notably, in 2009 he demonstrated in mice that these effects were not dependent on glucose lowering or weight loss – findings confirmed over a decade later in cardiovascular outcome trials. His discoveries predicted the safety of GLP-1 receptor agonists for their expanding applications to treat obesity and other chronic conditions. Most recently, Drucker has identified multiple mechanisms linking GLP-1 to the reduction of inflammation. Drucker holds the Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology. His many national and international recognitions include the 2023 Wolf Prize in Medicine, awarded for "pioneering work in elucidating the mechanisms and therapeutic potential of enteroendocrine hormones," as well as the Warren Alpert Foundation Prize and the Canada Gairdner International Award, among numerous others. Drucker was elected a Royal Society Fellow in 2015, a National Academy of Sciences International Member in 2021and a National Academy of Medicine International Member in 2023.
== Reconstitution of the tablets == The cuneiform tablets confirming Amat-Mamu's inheritance were stored in the home of her uncle, Ikun-pī-Sîn. They were kept separate from the family archive so as not to suggest that the inheritance was part of the family estate. It is unknown why they were kept in her uncle's house, though such storage arrangements with family members were not uncommon. When they were lost, her father Sîn-ilî had a deposition taken from the uncle admitting to their loss. Amat-Mamu was forced to go to the court so the judges could authorize the creation of new tablets. The tablets that Belessunu received as a girl during her own adoption were not reconstituted, for her and her witnesses to that contract had already died. The court also ruled that should the previous tablets be found, they were still the sole property of Amat-Mamu. The sequence of events describing both the legal dispute and the tablets' loss was documented on the reconstituted tablet. The reconstitution meant that some details were lost and inconsistencies were introduced, primarily in the description of the fields. The tablet is dated to the 14th year of Samsu-iluna's rule, placing its creation around 1736 BC. It has been preserved and is designated by archeologists as CT 47.63. Amat-Mamu's story is listed on the tablet alongside that of Belessunu, including Belessunu's dedication as a nadītu and her adoption by her aunt. The tablet is used in the modern era as a reference to understand Babylonian property and inheritance law.
Sources: en.wikipedia.org
== Soluble TCR == A soluble TCR is a TCR that has been made water-soluble using protein engineering. Such a protein is based on changing an existing TCR's chains to remove the transmembrane portions, leaving only the extracellular part. A number of techniques from protein engineering are then used to stabilize the complex and improve its binding characteristics. A soluble TCR can be used as an antigen-binding module, much like how monoclonal antibodies are used in medicine. Their advantage over antibodies is that they make use of the MHC/HLA display mechanism, allowing them to detect not only extracellular antigens, but also fragments of intracellular ones. On the other hand, they also face some restrictions in terms of applicable HLA genotypes due to them being made to target the complex of a MHC protein with the antigen fragment. One idea for overcoming this restriction is to instead target monomorphic HLA-like molecules such as HLA-E, MHC-related protein 1 (MR1) and cluster of differentiation 1 a, b, c and d (CD1a, CD1b, CD1c or CD1d). An example of a protein derived from soluble TCR is tebentafusp, approved by the US FDA in 2022. This designed protein contains a soluble TCR (αβ) targeting a fragment of gp100 presented by HLA-A*02:01 connected to a ScFv that binds CD3. As a result it causes T cells to activate in the vicinity of cells that present gp100, acting as a molecular glue (a bi-specific T-cell engager in the broad sense). It is only applicable to people with the HLA-A*02:01 genotype.
Official U.S. Senate website Lathrop & Gage LLP – People – Eric S. Schmitt biography at his law firm Biography at the Biographical Directory of the United States Congress Financial information (federal office) at the Federal Election Commission Legislation sponsored at the Library of Congress Profile at Vote Smart "Voter Information for Eric Schmitt. November 4, 2008 Election". SmartVoter. League of Women Voters of California Education Fund. Retrieved April 6, 2009. Appearances on C-SPAN
== FSH and LH preparations == hMG (human Menopausal Gonadotrophins), FSH and LH prepared from human urine collected from postmenopausal women. First extracted in 1953. Injected intra-muscularily (IM) or subcutaneously (SC). Generic
He added the Lusatias to the Lands of the Bohemian Crown, which then comprised large territories with a significant German population. In the hilly border regions German settlers established major manufactures of forest glass. The situation of the German population was aggravated by the Hussite Wars (1419–1434), though there were also some Germans among the Hussite insurgents. Despite the hardships of the Hussite Wars, the German population remained dominant in the border regions. By then Germans largely settled the hilly Bohemian border regions as well as the cities of the lowlands; mainly people of Bavarian descent in the South Bohemian and South Moravian Region, in Brno, Jihlava, České Budějovice and the West Bohemian Plzeň Region; Franconian people in Žatec; Upper Saxons in adjacent North Bohemia, where the border with the Saxon Electorate was fixed by the 1459 Peace of Eger; Germanic Silesians in the adjacent Sudetes region with the County of Kladsko, in the Moravian–Silesian Region, in Svitavy and Olomouc. The city of Prague had a German-speaking majority from the last third of the 17th century until 1860, but after 1910 the proportion of German speakers had decreased to 6.7% of the population. From the Luxembourgs, rule over Bohemia passed through George of Podiebrad to the Jagiellon dynasty and finally to the House of Habsburg in 1526. Both Czech and German Bohemians suffered heavily in the Thirty Years' War. Bohemia lost 70% of its population.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
Cold storage at minus twenty degrees Celsius or below is typical, with desiccant and protection from light. The solid form is far more stable than any solution.